The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
Por:
Bonanno, L, Costa, C, Majem, M, Sanchez, JJ, Gimenez-Capitan, A, Rodriguez, I, Vergnenegre, A, Massuti, B, Favaretto, A, Rugge, M, Pallares, C, Taron, M, Rosell, R
Publicada:
1 oct 2013
Resumen:
Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P < 0.0001) and overall survival was 8.2 months (P = 0.001). The expression of 53BP1 refines BRCA1-based predictive modeling to identify patients most likely to benefit from platinum-based chemotherapy.
Filiaciones:
Bonanno, L:
Ist Oncol Veneto IRCCS, Med Oncol Unit 2, Padua, Italy
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Costa, C:
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Majem, M:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Sanchez, JJ:
Univ Autonoma Madrid, Madrid, Spain
Gimenez-Capitan, A:
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Rodriguez, I:
USP Dexeus Univ Inst, Unidad Epidemiol & Estadist, Dept Obstet Ginecol & Reprod, Barcelona, Spain
Vergnenegre, A:
Cluzeau Hosp, Limoges, France
Massuti, B:
Hosp Gen Alicante, Alicante, Spain
Favaretto, A:
Ist Oncol Veneto IRCCS, Med Oncol Unit 2, Padua, Italy
Rugge, M:
Univ Padua, Dept Med, Surg Pathol & Cytopathol Unit, Padua, Italy
Pallares, C:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Taron, M:
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
Rosell, R:
USP Dexeus Univ Inst, Pangaea Biotech SL, Barcelona, Spain
Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Barcelona, Spain
Green Submitted, Green Published, hybrid
|